

Estimating the population health burden of musculoskeletal conditions using primary care electronic health records

YU, D., PEAT, George <<http://orcid.org/0000-0002-9008-0184>>, JORDAN, K.P., BAILEY, J., PRIETO-ALHAMBRA, D., ROBINSON, D.E., STRAUSS, V.Y., WALKER-BONE, K., SILMAN, A., MAMAS, M., BLACKBURN, S., DENT, S., DUNN, K., JUDGE, A., PROTHEROE, J. and WILKIE, R.

Available from Sheffield Hallam University Research Archive (SHURA) at:

<https://shura.shu.ac.uk/30539/>

This document is the Published Version [VoR]

Citation:



YU, D., PEAT, George, JORDAN, K.P., BAILEY, J., PRIETO-ALHAMBRA, D., ROBINSON, D.E., STRAUSS, V.Y., WALKER-BONE, K., SILMAN, A., MAMAS, M., BLACKBURN, S., DENT, S., DUNN, K., JUDGE, A., PROTHEROE, J. and WILKIE, R. (2021). Estimating the population health burden of musculoskeletal conditions using primary care electronic health records. *Rheumatology (United Kingdom)*, 60 (10), 4832-4843. [Article]

Copyright and re-use policy

See <http://shura.shu.ac.uk/information.html>

Original article

Estimating the population health burden of musculoskeletal conditions using primary care electronic health records

Dahai Yu ¹, George Peat^{1,2}, Kelvin P. Jordan^{1,3}, James Bailey¹, Daniel Prieto-Alhambra⁴, Danielle E. Robinson⁴, Victoria Y. Strauss⁴, Karen Walker-Bone^{2,5}, Alan Silman⁴, Mamas Mamas⁶, Steven Blackburn¹, Stephen Dent ⁷, Kate Dunn¹, Andrew Judge^{4,8}, Joanne Protheroe¹ and Ross Wilkie^{1,2}

Abstract

Objectives. Better indicators from affordable, sustainable data sources are needed to monitor population burden of musculoskeletal conditions. We propose five indicators of musculoskeletal health and assessed if routinely available primary care electronic health records (EHR) can estimate population levels in musculoskeletal consulters.

Methods. We collected validated patient-reported measures of pain experience, function and health status through a local survey of adults (≥ 35 years) presenting to English general practices over 12 months for low back pain, shoulder pain, osteoarthritis and other regional musculoskeletal disorders. Using EHR data we derived and validated models for estimating population levels of five self-reported indicators: prevalence of high impact chronic pain, overall musculoskeletal health (based on Musculoskeletal Health Questionnaire), quality of life (based on EuroQoL health utility measure), and prevalence of moderate-to-severe low back pain and moderate-to-severe shoulder pain. We applied models to a national EHR database (Clinical Practice Research Datalink) to obtain national estimates of each indicator for three successive years.

Results. The optimal models included recorded demographics, deprivation, consultation frequency, analgesic and antidepressant prescriptions, and multimorbidity. Applying models to national EHR, we estimated that 31.9% of adults (≥ 35 years) presenting with non-inflammatory musculoskeletal disorders in England in 2016/17 experienced high impact chronic pain. Estimated population health levels were worse in women, older aged and those in the most deprived neighbourhoods, and changed little over 3 years.

Conclusion. National and subnational estimates for a range of subjective indicators of non-inflammatory musculoskeletal health conditions can be obtained using information from routine electronic health records.

Key words: electronic health records, primary care, musculoskeletal, health services research, surveillance, pain, quality of life, back pain, shoulder pain

Rheumatology key messages

- There is a lack of data to estimate the population burden of musculoskeletal conditions.
- We developed and validated models to estimate population musculoskeletal health using primary care electronic health records.
- The study adds new national and regional estimates of indicators of musculoskeletal health.

¹Primary Care Centre Versus Arthritis, School of Medicine, Keele University, ²MRC Versus Arthritis Centre for Musculoskeletal Health and Work, University of Southampton, Southampton, ³Centre for Prognostic Research, Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Keele, ⁴Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford, ⁵MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, ⁶Keele Cardiovascular

Research Group, Centre for Prognosis Research, School of Medicine, Keele University, Keele, ⁷Public Contributor and ⁸Musculoskeletal Research Unit, University of Bristol, Bristol, UK
Submitted 22 October 2020; accepted 18 January 2021

Correspondence to: Dahai Yu, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele ST5 5BG, UK.
E-mail: d.yu@keele.ac.uk

Introduction

Musculoskeletal conditions such as low back pain (LBP) and osteoarthritis (OA) are extremely common, have proven over decades to be stubbornly resistant to treatment, and represent one of the greatest challenges to healthcare services and population health through their impact on everyday life [1]. Despite such overwhelming evidence of their significance, there is a lack of data that provide estimates of the extent of the impact of musculoskeletal conditions at a population level that can be used to guide interventions and preventative strategies.

Primary care electronic health records (EHR) offer the potential to be an ongoing source of data that can be used for surveillance and drive improvements in healthcare and health [2]. This ongoing collection of information can provide estimates of the number of people who have conditions and the processes of care such as the number that receive joint replacement or are prescribed pain medications and biologic therapies [2–5], although notably the availability of these data varies depending on geography and source (e.g. prescribed analgesics are well-recorded in primary care settings, joint replacement and biologic therapy are better recorded in secondary care data). However, the reason that people seek health care is not directly linked to the presence of musculoskeletal conditions but more so to the severity of symptoms (e.g. severity of pain) and their impact, in terms of disability and reduced quality of life [5], which drives the need for intervention and preventative strategies.

EHR does not routinely capture information on the severity or impact of musculoskeletal conditions and these data are best collected from patient reports [6, 7]. National surveys provide data on impact but have limited space for specific information on musculoskeletal conditions that can help with the prioritization of resources and services [2, 8, 9]. Combining EHR with patient reported information presents an opportunity to more accurately identify the impact of musculoskeletal conditions and the distribution and inequalities in the population [10]. However, patient reported information on musculoskeletal conditions may not always be available, and if EHR are to be used for ongoing surveillance, their ability to estimate the impact of musculoskeletal conditions must be examined [11].

In this study, the focus is on adults seeking healthcare for common musculoskeletal conditions. Five population indicators are proposed for surveillance of musculoskeletal health and that can be used to guide intervention strategies. The aim of this study was to examine if EHR data can estimate the extent of the impact of musculoskeletal conditions in musculoskeletal consulters at a population level.

Methods

Design

We conducted our investigation in three stages:

- i. A local census survey of all adults aged ≥ 35 years presenting to selected English general practices in one calendar year for non-inflammatory musculoskeletal conditions.
- ii. Using linked primary care EHR data from consenting respondents, we derived and internally validated one model each for estimating population-level estimates of five self-reported indicators—the prevalence of high impact chronic pain, musculoskeletal health (mean Musculoskeletal Health Questionnaire (MSK-HQ) score), quality of life [mean EuroQoL health utility score (EQ-5D-5L)], prevalence of moderate-to-severe chronic LBP among LBP consulters, prevalence of moderate-to-severe chronic shoulder pain among shoulder pain consulters
- iii. We applied our models using harmonized code lists to an independent national primary care EHR database (Clinical Practice Research Datalink) to obtain national and regional estimates of each indicator for three successive calendar years (2014/15, 2015/16 and 2016/17).

Population and setting

The target population was adults aged ≥ 35 years presenting to primary care with LBP, neck pain, osteoarthritis, non-specific hip pain, knee pain, shoulder pain or hand/wrist pain.

Musculoskeletal health indicators

Based on a review of national outcome frameworks [11, 12], existing indicators [13], proposed indicator sets for musculoskeletal health [14] and input from public contributors, we selected the following five musculoskeletal health indicators for this study:

- Proportion of MSK consulters with high impact chronic pain (HICP) defined as pain on most or all days in the previous 6 months and that limited life or work activities on most or all days. This approach is used in the US National Pain Survey [15].
- Mean Musculoskeletal Health Questionnaire (MSK-HQ) score: a 14-item questionnaire that captures key outcomes that patients with musculoskeletal conditions have prioritized as important for use across clinical pathways [16]. Scores range from 0 to 56, higher scores indicating better musculoskeletal health over the past 2 weeks [16].
- Mean EQ-5D-5L health utility score: the EQ-5D-5L self-classifier provides a self-reported description of health-related quality of life, rated on the day of response, according to a five-dimensional classification divided into five levels of perceived problem (no, slight, moderate, severe, unable). It has excellent psychometric properties [17]. We calculated the EQ-5D-5L utility score using the UK crosswalk value set [17], with scores ranging from <0.0 (representing health states worse than death) to 1.0 (full health).
- Proportion of LBP consulters with moderate-to-severe chronic LBP, defined as LBP present on most or all days in the previous 6 months *and* average intensity ≥ 5 on 0–10 NRS [18].

- Proportion of shoulder pain consulters with moderate-to-severe chronic shoulder pain, defined as shoulder pain present on most or all days in the previous 6 months and average intensity ≥ 5 on 0–10 NRS.

Data sources

PRELIM survey-EHR linked dataset

As part of the PRELIM project (<http://doi.org/10.21252/5ag3-ta31>), we conducted a cross-sectional survey of all adults aged ≥ 35 years who had been registered for at least 10 years at one of 11 general practices in two Clinical Commissioning Groups (CCGs) in North Staffordshire and Stoke-on-Trent, UK, and who, between 1 July 2016 and 30 June 2017, had an eligible consultation for LBP, neck pain, osteoarthritis, non-specific hip pain, knee pain, shoulder pain, or hand/wrist pain using pre-defined Read (morbidity) code lists (available from www.keele.ac.uk/mrr). The total population of the 11 practices aged 35 years and over was 72 009 (26% of all 35+ year-olds served by the two CCGs). Forty per cent of the population of North Staffordshire live in rural areas while 99% of Stoke-on-Trent is urban. Thirty per cent of Stoke-on-Trent neighbourhoods are in the most deprived decile in England, but 10 neighbourhoods, mostly in North Staffordshire, are in the most affluent decile. Relative to England, the resident population has less ethnic diversity; 91% identify as White, with Asian/Asian British the next most common ethnic group comprising 9% of the population of Stoke-on-Trent.

We excluded patients with recorded inflammatory disease, spondyloarthropathy or crystal arthropathy. The survey instrument contained recommended items and instruments measuring the nature, severity and impact of MSK conditions, including the five indicators described above [17]. At 2 weeks, non-responders were re-sent the survey and offered the option of online completion, and at 4 weeks a minimum data collection survey was mailed to non-respondents, again with the option of online completion. Of 8461 mailed, 4528 responded (response rate 54%). Of these, 3828 (85%) consented to link their survey responses to routinely collected primary care EHR data, and 3710 (97%) had completed self-reported musculoskeletal health indicators. The general practices had all previously contributed to the CiPCA (North Staffordshire) primary care EHR database, which included training and assessment in morbidity recording [19], and been previously shown to give similar annual consultation prevalence rates for musculoskeletal conditions as national and international EHR databases [20, 21].

Covariates considered for inclusion in the models to estimate each of the five indicator measures were selected based on previous literature, expert opinion (including that of patients), potential association with MSK health status and routinely recorded within primary care EHR. These included demographic, socioeconomic, lifestyle, comorbidity, and musculoskeletal/pain-specific

primary care contacts, diagnoses/problem codes, referrals, investigations and treatments (Table 1). A data manager independent from, and blinded to, survey data extracted these candidate covariates from the EHR of consenting respondents using pre-defined code lists (available from the authors; for the period up to 10 years prior to the survey). Details for definition of all candidate covariates are presented in Supplementary Table 1, available at *Rheumatology* online. Briefly, lifestyle predictors (i.e. smoking status, BMI), the most recent record before the index date was used; other candidate covariates were defined as having any record within 10 year prior to the survey (i.e. the Charlson Comorbidity Index was solely defined by Read codes, without combining other function or evaluation procedures).

These data were then linked to survey data to create the PRELIM Survey.

Clinical practice research datalink national EHR data

Clinical practice research datalink (CPRD) GOLD contains EHR data from over 10 million patients registered with over 650 UK general practices [22]. For this study we used data from practices (all in England) which consented to linkage to the Index of Multiple Deprivation (IMD) [23]. Based on patient's residential postcode, IMD is a composite measure of neighbourhood deprivation incorporating domains on income, employment, education, health, housing, crime, and environment. Using code lists for eligibility criteria that were harmonized with those used in PRELIM Survey-EHR we included adults aged ≥ 35 years ($n = 49\,788$) consulting for a non-inflammatory musculoskeletal pain condition in July 2016–June 2017 (i.e. as per PRELIM). Using another set of harmonized code lists we extracted information on their covariates recorded in the previous 10 years. We then repeated this process for cases consulting between July 2015 and June 2016 and between June 2014 and July 2015 to evaluate the stability over time of our modelled estimates.

Statistical analysis

Model development and internal validation

Using data from the PRELIM Survey-EHR data, we derived and internally validated multivariable models for each indicator. Multivariable logistic regression was used to model the three binary indicators (high impact chronic pain, moderate-to-severe chronic LBP, moderate-to-severe chronic shoulder pain). Multivariable linear regression was used to model MSK-HQ and EQ-5D-5L scores with these two indicators first transformed ($\text{MSK-HQ}^{0.5}$, $e^{\text{EQ-5D-5L}}$). For the comorbidity and prescription covariates, the lack of a record was presumed as absence (i.e. no diagnosis or prescription). For BMI, missing data were categorized as 'not recorded', along with the categories of healthy/underweight ($\text{BMI} < 25 \text{ kg/m}^2$), overweight ($25 \text{ kg/m}^2 \leq \text{BMI} < 30 \text{ kg/m}^2$), and obese ($\text{BMI} \geq 30 \text{ kg/m}^2$). Similarly, 'not recorded' was added as a category for drinking and smoking status. Multiple imputation was not used as the absence of a record of

TABLE 1 Descriptive characteristics and covariate distributions^a in musculoskeletal consultant cohorts, 2016–2017

MSK health indicator(s) of interest	MSK consultants ^b aged 35+ years, 2016–2017		Low back pain consultants aged 35+ years, 2016–2017		Shoulder pain consultants aged 35+ years, 2016–2017	
	PRELIM Survey-EHR	CPRD	PRELIM Survey-EHR	CPRD	PRELIM Survey-EHR	CPRD
Data source						
<i>n</i>	3710	49 788	1046	15 153	604	9690
Age, median (IQR), years	67 (57–75)	61 (52–72)	65 (55–74)	59 (49–71)	66 (57–74)	61 (52–72)
Female	2191 (59)	28 880 (58)	620 (59)	8907 (59)	346 (57)	5564 (57)
Index of multiple deprivation						
Quintile 1 (most deprived)	626 (17)	6909 (14)	185 (18)	2524 (17)	110 (18)	1314 (14)
Quintile 2	575 (15)	7818 (16)	157 (15)	2630 (17)	83 (14)	1469 (15)
Quintile 3	748 (20)	8988 (18)	211 (20)	2813 (19)	120 (20)	1745 (18)
Quintile 4	1184 (32)	10 153 (20)	328 (31)	2949 (19)	196 (33)	1993 (21)
Quintile 5 (least deprived)	630 (17)	15 920 (32)	165 (16)	4237 (28)	95 (16)	3169 (33)
MSK site-specific pain/condition						
Neck pain	897 (24)	11 487 (23)	211 (20)	2465 (16)	120 (20)	1798 (19)
Shoulder pain	1129 (30)	16 306 (33)	221 (21)	3044 (20)	—	—
Back pain	1793 (48)	25 559 (51)	—	—	199 (33)	3603 (37)
Hip pain	847 (23)	7583 (15)	199 (19)	2054 (14)	87 (14)	1242 (13)
Knee pain	1574 (42)	21 876 (44)	293 (28)	3668 (24)	192 (32)	2597 (27)
Hand pain	1008 (27)	9483 (19)	205 (20)	1724 (11)	125 (21)	1258 (13)
Osteoarthritis	1445 (39)	9894 (20)	259 (25)	1634 (11)	189 (31)	1337 (14)
Time since 1st MSK consultation, median (IQR), days: median (IQR)	1179 (483–1590)	1053 (310–1549)	1228 (518–1620)	1,094 (323–1563)	1,283 (552–1,629)	1,066 (316–1,562)
Time since last MSK consultation, median (IQR), days: median (IQR)	132 (97–162)	150 (66–253)	131 (97–161)	143 (59–245)	136 (97–162)	140 (59–240)
Number of MSK consultations: , median (IQR)	5 (2–9)	3 (2–6)	5 (3–10)	3 (2–6)	5 (3–10)	4 (2–6)
Any analgesic prescription	3,051(82)	36 048(72)	877(84)	11 983(79)	485(80)	6,828(71)
Highest-level of analgesic prescription:						

(continued)

TABLE 1 Continued

MSK health indicator(s) of interest	MSK consulters ^b aged 35+ years, 2016–2017		Low back pain consulters aged 35+ years, 2016–2017		Shoulder pain consulters aged 35+ years, 2016–2017	
	PRELIM Survey-EHR	CPRD	PRELIM Survey-EHR	CPRD	PRELIM Survey-EHR	CPRD
			% with moderate-to-severe chronic low back pain			
			% with moderate-to-severe chronic shoulder pain			
			5L score			
No analgesics	659(18)	13 740(28)	169(16)	3,170(21)	119(20)	2,862(30)
Basic analgesics	561(15)	5,445(11)	113(11)	1,101(7)	82(14)	1,055(11)
Weak analgesics	420(11)	4,469(9)	115(11)	1,326(9)	69(11)	808(8)
Moderate analgesics	424(11)	3,834(8)	127(12)	1,264(8)	67(11)	743(8)
Strong/very strong analgesics	1,646(44)	22 300(45)	522(50)	8,292(55)	267(44)	4,222(44)
NSAIDs prescription	1,331(35)	25 878(52)	428(41)	8,637(57)	223(37)	5,270(54)
Antidepressant prescription	1,396(37)	28 615(58)	465(45)	9,319(62)	240(40)	5,578(58)
Sedative prescription	221(6)	6,446(13)	73(7)	2,158(14)	41(7)	1,322(14)
Muscle relaxant prescription	51(1)	8,582(17)	24(2)	3,717(25)	5(1)	1,530(16)
Any MSK referral	1,400(37)	31 416(63)	404(39)	9,169(61)	237(39)	6,516(67)
MSK X-ray	2,107(56)	19 160(38)	492(47)	5,919(39)	339(56)	1,468(15)
MSK MRI	121(3)	2745(6)	53(5)	1293(9)	19(3)	215(2)
MSK surgery	527(14)	8179(16)	137(13)	1954(13)	68(11)	1943(20)
Joint injection	308(8)	3847(8)	75(7)	1027(7)	76(13)	1144(12)
Fracture	157(4)	3348(7)	49(5)	1006(7)	20(3)	622(6)
Impact on work (recorded fit-note)	956(25)	4067(8)	326(31)	1408(9)	152(25)	782(8)
BMI						
Healthy/underweight (<25 kg/m ²)	320(9)	11 022(22)	109(10)	3494(23)	69(11)	2191(23)
BMI not recorded	535(14)	10 880(22)	150(15)	3325(22)	69(11)	2064(21)
Overweight (25–29.9 kg/m ²)	1603(43)	13 871(28)	642(61)	4163(28)	395(65)	2774(29)
Obese (≥30 kg/m ²)	1292(34)	14 074(28)	124(12)	4171(28)	71(12)	2661(28)
Smoking status						
Non-smoker	1435(39)	21 390(43)	351(34)	6120(40)	244(40)	4270(44)
Smoking status not recorded	324(9)	5726(12)	254(24)	1669(11)	46(8)	1066(11)
Ex-smoker	716(19)	14 257(29)	156(15)	4328(29)	114(19)	2765(29)
Current smoker	1235(32)	8415(17)	285(27)	3036(20)	200(33)	1589(16)
Drinking status						
Non-drinker/drinking status not recorded/ex-drinker	1785(48)	2470(53)	213(20)	8237(54)	116(19)	5120(53)
Current Drinker	1925(52)	23 408(47)	833(80)	6916(46)	488(81)	4570(47)
Charlson Comorbidity Index (0–37)	0(0–2)	0(0–1)	0(0–1)	0(0–1)	0(0–1)	0(0–1)
eFI score (0–10): median (IQR)	0.08(0.06–0.14)	0.06(0.03–0.11)	0.08(0.06–0.14)	0.06(0.03–0.11)	0.08(0.03–0.14)	0.06(0.03–0.08)
Anxiety or depression consultation	751(20)	10 736(22)	253(24)	3,759(25)	118(20)	2,123(22)

Data are *n* (%), unless otherwise stated. Mean MSK-HQ and Mean EQ-5D-5L are outcomes (indicators) were both derived from MSK consultant cohorts. ^aCovariates were defined within a 5-year look back period in each cohort members' electronic health record (i.e. 60 months prior to 30 June 2017). ^bDefined as non-specific, non-inflammatory low back pain, neck pain, shoulder pain, hand/wrist pain, hip pain, knee pain or osteoarthritis. eFI: electronic frailty index; IQR: interquartile range; MSK: musculoskeletal.

these covariates may be associated with the value of the outcome indicator. Multivariable fractional polynomials were used for modelling potential non-linear relationships between continuous covariates and outcomes.

We first determined the optimal number of years prior to MSK consultation (the 'look-back' period) needed to identify covariates in the EHR. For each indicator we fitted 10 full models (all covariates included) using 1–10 years of retrospective EHR data to define the covariates. The look-back period with best model performance after assessment of Akaike information criterion, Bayesian information criterion, R^2 and C-statistics (for binary indicators) was chosen. For the final parsimonious models using the optimal look-back period, covariates were dropped through backward stepwise elimination ($P > 0.2$, based on change in log likelihood), with age and gender retained in all models. Finally, interactions of included covariates with age were assessed to see if they improved the model.

Model performance

For subgroups of the population based on age, gender, CCG and deprivation, we compared the observed prevalence rates and mean scores (as appropriate) of the indicators from the PRELIM survey with their estimated values derived from the models utilizing the linked EHR. For logistic regression models, performance of the final model was also examined using the C-statistic. For linear regression models, performance was assessed using R^2 (proportion of the variance in continuous outcomes explained by the included covariates).

Final models were applied to 100 bootstrapped samples to examine performance (as described above), and then to the original dataset to test model performance and optimism (the difference in the performance in the bootstrapped and original data). Overall optimism was estimated for all models. The overall optimism-corrected calibration of these models was assessed graphically by plotting agreement between predicted and observed values for each decile of predicted risk.

Application of models to national EHR data

The final parsimonious, optimism-corrected models derived in the PRELIM Survey-EHR data were then applied to the relevant MSK consultant cohorts in the CPRD dataset to estimate the prevalence/mean of each of the five indicators for national estimates in three consecutive years: 2014/15, 2015/16 and 2016/17. For the three binary indicators, the estimated prevalence was the mean of the estimated individual probabilities in the specific population. For the continuous indicators, the estimated mean was the mean of the estimated individual scores [transformed back from estimates in the linear regression, as $(\text{MSK-HQ}^{0.5})^2$ for MSK-HQ and $\ln(e^{\text{EQ-5D-5L}})$ for EQ-5D-5L] in the specific population. We present these estimates overall, and stratified by sex, age (10-year age bands), deprivation (quintiles) and geographical region.

To explore the sensitivity of our findings to length of look-back period, we repeated all the preceding steps using a 2-year look-back period in the EHR data.

Ethical approval

Ethical approval was obtained for the PRELIM survey and linkage to primary care EHR data from the North West-Greater Manchester East Research Ethics Committee (REC Ref: 15/NW/0735). The use of CPRD was approved by the Independent Scientific Advisory Committee (reference number: 18_014).

Patient and public involvement

Public contributors were involved throughout this study to ensure that the perspectives of patients remained at the centre of the research. Ten public contributors from the Research User Group, Keele University, were involved in the study, as part of advisory groups or study management meetings. They provided patient perspectives on the development of the proposal (particularly on linkage of data from EHR and questionnaires), study materials (participation information sheets, consent forms) and the PRELIM questionnaire. A public co-applicant (S.D.) is a member of the study team and two other public contributors attended the study steering committee.

Results

Model development and apparent performance—PRELIM Survey-EHR

Based on consistently good relative model fit and performance, the 5-year look-back period for identifying covariates recorded in the EHR was selected as optimal for all indicators, although differences between look-back periods were generally small (Supplementary Fig. 1, available at *Rheumatology* online). Distribution of the covariates over the 5-year period in the PRELIM Survey-EHR cohort are given in Table 1.

After backward elimination, between 7 and 16 covariates were retained in each model (minimum of 14 events per parameter in logistic regression models and 143 subjects per parameter in linear regression models). The coefficients of the models are given in Supplementary Table 2, available at *Rheumatology* online. Prescription of strong or very strong analgesia was strongly associated with all five indicators while antidepressant prescriptions, time since MSK consultation and area-level deprivation were strongly associated with four of the five indicators. Any MSK referral and joint injection were associated with moderate-to-severe chronic low back pain and EQ-5D-5L, respectively. MSK X-ray and smoking were associated with moderate-to-severe chronic shoulder pain. The non-linear associations of continuous covariates with indicators is shown in Supplementary Fig. 2, available at *Rheumatology* online.


Absolute differences between observed and estimated prevalence rates and means when stratified by age, sex,

TABLE 2 England national and subnational estimates for MSK health indicators based on application of final models

MSK health indicator	MSK consultants ^a aged 35+ years										Low back pain consultants aged 35+ years					Shoulder pain consultants aged 35+ years									
	% with high impact chronic pain					Mean MSK-HQ score (0–56)					Mean EQ-5D-5L score (–0.224 to 1)					% with moderate-to-severe chronic back pain					% with moderate-to-severe chronic shoulder pain				
	2014/15	2015/16	2016/17	2014/15	2015/16	2016/17	2014/15	2015/16	2016/17	2014/15	2015/16	2016/17	2014/15	2015/16	2016/17	2014/15	2015/16	2016/17	2014/15	2015/16	2016/17				
Overall (crude)	33.3	32.1	31.9	33.5 (7.8)	33.7 (7.9)	33.8 (8.0)	0.60 (0.15)	0.62 (0.15)	0.66 (0.14)	27.4	25.8	26.0	29.7	27.4	27.8	29.7	27.4	27.8	29.7	27.4	27.8				
Men	31.6	30.6	30.4	34.5 (7.9)	34.6 (8.0)	34.8 (8.0)	0.62 (0.14)	0.63 (0.15)	0.67 (0.14)	25.9	24.0	24.4	28.1	25.8	26.6	28.1	25.8	26.6	28.1	25.8	26.6				
Women	34.6	33.2	33.0	32.8 (7.7)	33.0 (7.8)	33.2 (7.9)	0.59 (0.15)	0.61 (0.15)	0.66 (0.15)	28.5	27.0	27.2	31.0	28.6	28.7	31.0	28.6	28.7	31.0	28.6	28.7				
Age Group																									
35–44 years	30.2	30.0	29.2	32.9 (8.0)	32.8 (8.1)	33.1 (8.2)	0.64 (0.15)	0.64 (0.15)	0.73 (0.13)	27.4	26.5	25.7	25.5	23.9	23.8	25.5	23.9	23.8	25.5	23.9	23.8				
45–54 years	29.4	28.9	28.9	34.0 (8.2)	34.2 (8.2)	34.1 (8.4)	0.65 (0.15)	0.65 (0.15)	0.72 (0.14)	25.9	24.6	25.5	26.2	24.2	24.1	26.2	24.2	24.1	26.2	24.2	24.1				
55–64 years	30.2	28.8	28.9	34.6 (8.1)	34.8 (8.2)	34.9 (8.3)	0.64 (0.14)	0.65 (0.15)	0.71 (0.14)	26.4	24.6	25.1	28.7	26.5	27.4	28.7	26.5	27.4	28.7	26.5	27.4				
65–74 years	33.5	32.2	32.2	33.9 (7.7)	34.1 (7.7)	34.2 (7.8)	0.61 (0.14)	0.62 (0.14)	0.68 (0.14)	26.9	25.1	25.6	31.6	29.3	30.2	31.6	29.3	30.2	31.6	29.3	30.2				
75–84 years	39.7	37.8	37.8	32.1 (7.0)	32.3 (7.0)	32.5 (7.2)	0.57 (0.14)	0.57 (0.14)	0.64 (0.14)	30.0	27.9	27.3	34.8	31.1	31.7	34.8	31.1	31.7	34.8	31.1	31.7				
85+ years	45.5	44.1	44.5	30.4 (6.2)	30.3 (6.3)	30.3 (6.2)	0.50 (0.14)	0.51 (0.13)	0.58 (0.14)	33.4	31.3	32.2	31.7	31.0	30.1	31.7	31.0	30.1	31.7	31.0	30.1				
Index of multiple deprivation																									
Quintile 1 (most)	42.9	42.2	41.4	28.4 (6.4)	28.3 (6.5)	28.6 (6.6)	0.54 (0.15)	0.52 (0.14)	0.62 (0.15)	37.5	35.7	36.3	33.3	30.7	30.5	33.3	30.7	30.5	33.3	30.7	30.5				
Quintile 2	33.3	32.5	32.0	32.3 (7.3)	32.3 (7.3)	32.4 (7.3)	0.59 (0.14)	0.60 (0.14)	0.68 (0.14)	23.3	22.1	21.7	29.7	29.0	29.6	29.7	29.0	29.6	29.7	29.0	29.6				
Quintile 3	36.4	35.2	35.1	33.2 (7.4)	33.4 (7.4)	33.3 (7.5)	0.60 (0.14)	0.61 (0.14)	0.68 (0.14)	27.7	26.9	26.7	30.1	27.9	28.5	30.1	27.9	28.5	30.1	27.9	28.5				
Quintile 4	31.2	29.9	30.2	34.6 (7.6)	34.7 (7.6)	34.7 (7.6)	0.64 (0.14)	0.64 (0.14)	0.70 (0.14)	25.9	23.9	24.4	28.8	26.0	27.7	28.8	26.0	27.7	28.8	26.0	27.7				
Quintile 5 (least)	27.4	26.6	27.1	36.5 (7.8)	36.4 (7.9)	36.4 (7.9)	0.69 (0.14)	0.67 (0.14)	0.72 (0.13)	24.8	23.2	23.3	28.1	25.7	25.4	28.1	25.7	25.4	28.1	25.7	25.4				
Region																									
North East	37.6	35.5	39.8	31.7 (7.5)	31.9 (7.1)	30.6 (7.4)	0.58 (0.15)	0.59 (0.14)	0.65 (0.16)	31.6	30.3	38.5	31.1	31.2	39.3	31.1	31.2	39.3	31.1	31.2	39.3				
North West	36.2	34.8	34.0	31.9 (7.5)	32.1 (7.6)	32.4 (7.7)	0.59 (0.14)	0.59 (0.15)	0.68 (0.14)	30.0	28.2	26.6	31.3	27.8	27.3	31.3	27.8	27.3	31.3	27.8	27.3				
Yorkshire and Humber	36.8	32.8	30.9	31.8 (7.4)	32.8 (7.7)	33.4 (7.7)	0.59 (0.14)	0.61 (0.14)	0.71 (0.14)	28.3	23.2	23.9	32.3	29.2	26.2	32.3	29.2	26.2	32.3	29.2	26.2				
East Midlands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—				
West Midlands	33.5	32.8	33.2	33.5 (7.7)	33.2 (7.8)	33.2 (7.7)	0.62 (0.15)	0.64 (0.15)	0.68 (0.14)	28.3	27.9	28.5	30.9	28.5	29.0	30.9	28.5	29.0	30.9	28.5	29.0				
East of England	31.3	30.0	30.5	34.5 (7.8)	34.9 (8.0)	34.5 (8.2)	0.63 (0.15)	0.61 (0.15)	0.70 (0.14)	27.1	24.9	24.3	30.4	28.1	28.6	30.4	28.1	28.6	30.4	28.1	28.6				
South West	35.7	34.4	35.2	32.7 (7.8)	32.9 (7.8)	32.5 (7.9)	0.60 (0.15)	0.61 (0.15)	0.68 (0.15)	29.6	28.6	29.5	31.1	29.4	31.1	31.1	29.4	31.1	31.1	29.4	31.1				
South Central	31.6	30.5	29.4	34.5 (7.9)	34.7 (7.9)	35.3 (8.0)	0.63 (0.14)	0.64 (0.15)	0.70 (0.14)	25.9	24.0	25.1	29.2	26.4	28.7	29.2	26.4	28.7	29.2	26.4	28.7				
London	31.8	30.8	30.8	33.8 (8.0)	33.8 (8.0)	33.9 (8.1)	0.62 (0.14)	0.62 (0.15)	0.69 (0.15)	25.9	24.4	24.3	27.9	26.1	24.8	27.9	26.1	24.8	27.9	26.1	24.8				
South East Coast	32.0	31.4	31.1	34.2 (8.0)	34.1 (7.9)	34.4 (8.0)	0.63 (0.14)	0.63 (0.15)	0.70 (0.14)	25.1	24.3	24.7	27.3	26.6	26.6	27.3	26.6	26.6	27.3	26.6	26.6				

Data source: Clinical Practice Research Datalink (CPRD). Covariates were defined using 5-year look back period. ^aDefined as non-specific, non-inflammatory low back pain, neck pain, shoulder pain, hand/wrist pain, hip pain, or osteoarthritis. EQ-5D-5L: EuroQoL 5 dimensions, 5-level version; MSK: musculoskeletal; MSK-HQ: Musculoskeletal Health Questionnaire.

Fig. 1 Difference between observed and estimated prevalence/mean score for each MSK Health indicator by gender, age, deprivation and Clinical Commissioning Group (CCG)



(A) High impact chronic pain. **(B)** Moderate-to-severe chronic low back pain. **(C)** Moderate-to-severe chronic shoulder pain. **(D)** MSK-HQ score. **(E)** EQ-5D-5L score.

CCG and deprivation are presented in Fig. 1. Estimated prevalence varied from that observed by a maximum of 5% for high impact chronic pain, moderate-to-severe chronic shoulder pain and moderate-to-severe chronic LBP; and mean scores by ± 0.2 for MSK-HQ score and ± 0.01 for EQ-5D-5L score. The optimism-corrected C-statistics for the three prediction models for binary MSK health indicators ranged from 0.74 to 0.77, while for the two continuous indicators the optimism-corrected R^2 values were 0.30 and 0.33 (Supplementary Table 3, available at *Rheumatology* online). The optimism-corrected calibration slopes were all 0.99 and with good agreement between observed and estimated prevalence rates and means.

National estimates of MSK indicators

Compared with MSK consulters recorded in CPRD, participants in the PRELIM Survey-EHR cohort were older, and more likely to live in deprived neighbourhoods (Table 1). They were also more likely to have previous recorded MSK consultations in the hand and hip and for osteoarthritis, analgesic prescriptions and MSK X-ray. However, the level of recorded prescriptions for NSAIDs, antidepressants, muscle relaxants and sedatives as well as MSK referrals were lower.

By applying our final PRELIM-derived models in CPRD, we estimated nationally that 31.9% of adults aged 35 years and over who had consulted for a common non-inflammatory musculoskeletal pain condition in 2016–2017 would be experiencing high impact chronic pain (Table 2). The estimated mean MSK-HQ and EQ-5D-5L scores in these MSK consulters were 33.8 and 0.66, respectively. Among recent LBP consulters, an estimated 26.0% had moderate-to-severe chronic LBP. Of recent shoulder pain consulters, an estimated 27.8% had moderate-to-severe chronic shoulder pain. Across all indicators, MSK health among consulters was worse in women than in men, with older age, and in those living in the most deprived neighbourhoods. Over the three consecutive years from 2014/15 to 2016/17 age-, sex- and deprivation-specific estimates for all indicators showed either no or small improvements with greatest increases seen in mean EQ-5D-5L scores in all strata. The sensitivity analysis using a shorter 2-year look-back period for covariates gave similar estimates and patterns, although a slightly lower prevalence of high impact chronic pain (28.9% vs 31.9% in 2016/17) and a slightly higher prevalence of moderate-to-severe chronic LBP (29.2% vs 26.0%) (Supplementary Table 4, available at *Rheumatology* online).

Discussion

Summary of main findings

Our study provides evidence that it is feasible to use routinely collected EHR data to estimate the extent of the impact of musculoskeletal conditions in populations to guide interventions and healthcare planning. While

the remit of our study was specifically five selected indicators on the severity and impact of common, non-inflammatory musculoskeletal disorders, the methodology is likely to be generalizable to other indicators and other musculoskeletal conditions.

Comparison with previous research

To our knowledge this is the first study to use prediction model methodology based on routine EHR data to estimate the prevalence and distribution of patient-reported severity and impacts of musculoskeletal conditions. Efforts to classify the severity of long-term musculoskeletal conditions from information in the EHR [24] are based on the expectation that severity can be meaningfully inferred from available patterns of coded events and processes. Our approach extends this by directly modelling patient-reported measurement of severity to obtain population-level estimates of health. Primary care EHRs currently contain little systematic measurement of pain severity, functional status, wellbeing and quality of life. As a result, there are few direct comparisons for the estimates provided here. UK and US surveys estimate the prevalence of moderately severely disabling chronic pain/high impact chronic pain in the adult general population at between 10 and 16% [25]. Our estimate of 32% with high impact chronic pain among MSK consulters aged over 35 years reflects the older age range in our study but more crucially the selection of a high-risk group (MSK consulters). Where comparable estimates exist in MSK consenter populations, our estimates appear similar. For example, our estimated mean MSK-HQ and EQ-5D-5L scores of 33.8 and 0.66 among MSK consulters were just slightly higher (indicating better MSK health) than those reported in a study of adult musculoskeletal patients referred to community physiotherapy clinics (30.5 and 0.60, respectively) [26]. Our estimated EQ-5D-5L mean score is higher than that from the General Practice Patient Survey (0.577) [13], which is likely to reflect the fact that the former is restricted to adults reporting a long-term MSK problem. The current indicator for the prevalence of 'severe back pain' used in the PHE Fingertips tool is also applied to those with a long-term back problem and uses a lower threshold for defining 'severe'. Our estimates show the expected pattern of worse MSK health in females, older ages, and those living in more deprived neighbourhoods.

Strengths and limitations

Our study illustrates an approach to producing timely, affordable indicators of the non-fatal impacts of musculoskeletal conditions that could be derived from continuous EHR data at national and subnational levels. It highlights the potential benefits of such an approach to inform health system responses to the growing challenge of musculoskeletal conditions, which have historically received less attention than other conditions. We deliberately focused on the subpopulation of adults

aged ≥ 35 years who had a record of a non-inflammatory MSK consultation in the previous year. Our estimates do not therefore cover younger ages or those suffering MSK conditions but not presenting to primary healthcare in a given year of interest. Our survey, designed with the involvement of patients and members of the public, provided rich self-reported information on musculoskeletal health from nearly 4000 adults, with a response rate equivalent to that of the Health Survey for England (HSE) [27], and substantially higher than the national GP Patient Survey [28]—both sources currently used to produce national musculoskeletal health indicators in England. A high proportion of respondents consented to EHR linkage in practices with a history of high-quality coding. Our public contributors improved the clarity of the study materials for participants and identified key areas for inclusion in the study questionnaire. Our public co-applicant (and co-author) provided the patient perspective on study decision-making. However, our local sampling frame is known to under-represent black, Asian and minority ethnic groups compared with the national average. Future enriched sampling of these groups or a shift to nationally representative survey sample frames with EHR linkage is needed. We found that models based on 5 years of continuous retrospective records were generally optimal but excluding patients and practices with <5 years' prior registration does reduce the sample size and has the potential to introduce selection bias. We used 5 years for all models for consistency. Other indicators or conditions may require fewer years of continuous records. In our study, models requiring only 2 years of retrospective records were only marginally inferior and we have provided these in full in [Supplementary data](#), available at *Rheumatology* online. The models rely on consistent coding of the included covariates. Lifestyle information, in particular, can often be missing from these records, but completeness has been improving over recent years. Performance of models could be improved by including information from the unstructured free text within the EHR [29] but access to this is increasingly difficult for researchers in the UK due to information governance restrictions. The prediction models have been derived using retrospective data and are limited in their application at the individual level to identify those at high risk. A prospective cohort design would be able to yield more discriminated and calibrated prediction model to identify high-risk individuals.

Implications for research and practice

The need to integrate patient-reported outcomes into EHRs has received considerable attention, but typically from the standpoint of clinical care and organisation of health services. We hope that our study stimulates further research on the harnessing of data within the EHR for population musculoskeletal health indicators and greater attention within health policy and practice to preventing and reducing disability associated with common musculoskeletal conditions in the population. Our

national estimates confirm the significant impact of musculoskeletal pain. Future external validation of our models, including research that explores how frequently such models may need to be updated in response to changing patterns of healthcare use and recording, and validation in other geographical areas with health record collation and linkage (such as in Scotland and Wales), are encouraged. Future studies using EHR to estimate the impact of MSK conditions on work ability are also warranted.

Conclusion

Information routinely recorded within English care EHR can estimate the prevalence and extent of key patient-reported measures of musculoskeletal health among adult consulters with acceptable accuracy. This approach could provide a sustainable, timely source for a richer array of population musculoskeletal health indicators to inform and support health policy and practice.

Acknowledgements

This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare Products Regulatory Agency. The data are provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the authors alone. We are extremely grateful for the input of our public contributors to the study. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. D.Y.: conceptualization, data curation, formal analysis, investigation, methodology, resources, validation, visualization, writing—original draft, writing—review and editing. G.P., K.P.J., R.W.: conceptualization, data curation, investigation, methodology, resources, validation, visualization, writing—original draft, writing—review and editing. J.B., D.P.-A., D.E.R., V.Y.S., K.W.-B., A.S.: conceptualization, methodology, resources, validation, visualization, writing—review and editing. M.M., S.B., S.D., K.D., A.J., J.P.: conceptualization, methodology, resources, validation, writing—review and editing.

Ethics

Ethical approval was obtained for the PRELIM survey and linkage to primary care EHR data from the North West-Greater Manchester East Research Ethics Committee (REC Ref : 15/NW/0735). The use of CPRD was approved by the Independent Scientific Advisory Committee (reference number: 18_014).

Funding: PRELIM was funded by Versus Arthritis (21403). G.P., K.J., R.W. and D.Y. hold Honorary

Academic Consultant Contracts from Public Health England. K.J. is supported by matched funding awarded to the NIHR Applied Research Collaboration (West Midlands). This research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). D.P.A. is funded through a NIHR Senior Research Fellowship (Grant Number SRF-2018-11-ST2-004). A.J. was supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol.

Disclosure statement: The authors declare no conflicts of interests.

Data availability statement

Available upon request.

Supplementary data

[Supplementary data](#) are available at *Rheumatology* online.

References

- Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;386:743-800.
- Calman N, Hauser D, Lurio J, Wu WY, Pichardo M. Strengthening public health and primary care collaboration through electronic health records. *Am J Public Health* 2012;102:e13-18.
- Hemingway H, Feder GS, Fitzpatrick NK *et al.* Using nationwide 'big data' from linked electronic health records to help improve outcomes in cardiovascular diseases: 33 studies using methods from epidemiology, informatics, economics and social science in the ClinicAI Disease Research Using Linked Bespoke Studies and Electronic Health Records (CALIBER) programme. *Programme Grants Appl Res* 2017;5:1-330.
- Schinasi LH, Auchincloss AH, Forrest CB, Diez Roux AV. Using electronic health record data for environmental and place based population health research: a systematic review. *Ann Epidemiol* 2018;28:493-502.
- Duenas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. *J Pain Res* 2016;9:457-67.
- Institute of Medicine. *Capturing Social and Behavioral Domains and Measures in Electronic Health Records: Phase 2*. Washington, DC: The National Academies Press, 2014.
- Jensen RE, Rothrock NE, DeWitt EM *et al.* The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. *Med Care* 2015;53:153-9.
- Mindell J, Biddulph JP, Hirani V *et al.* Cohort profile: the health survey for England. *Int J Epidemiol* 2012;41:1585-93.
- Abbott O. 2011 UK Census coverage assessment and adjustment methodology. *Popul Trends* 2009;(137):25-32.
- Steele L, Lade H, McKenzie S, Russell TG. Assessment and diagnosis of musculoskeletal shoulder disorders over the internet. *Int J Telemed Appl* 2012; 2012:945745.
- HM Government. *Help Shape Our Future: The 2021 Census of Population and Housing in England and Wales*. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/765089/Census2021WhitePaper.pdf (22 September 2020, data last accessed).
- Public Health England. *Public Health Outcomes Framework 2020*. (22 September 2020, date last accessed).
- Public Health England. *Fingertips Tool*. (22 September 2020, date last accessed).
- Chesterfield: *Versus Arthritis. MSK Recommended Indicator Set for Health Care Professionals*. 2015.
- Von Korff M, Scher AI, Helmick C *et al.* United States National Pain Strategy for Population Research: concepts, definitions, and pilot data. *J Pain* 2016;17:1068-80.
- Hill JC, Kang S, Benedetto E *et al.* Development and initial cohort validation of the Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal care pathways. *BMJ Open* 2016; 6:e012331.
- Mulhern B, Feng Y, Shah K *et al.* Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets. *Pharmacoeconomics* 2018;36:699-713.
- Gudin J, Rauck R, Argoff C, Agaiby E, Gimbel J, Katz N *et al.* Long-term safety and tolerability of NKTR-181 in patients with moderate to severe chronic low back pain or chronic noncancer pain: a phase 3 multicenter, open-label, 52-week study (SUMMIT-08 LTS). *Pain Med* 2020; 21:1347-56.
- Porcheret M, Hughes R, Evans D *et al.* Data quality of general practice electronic health records: the impact of a program of assessments, feedback, and training. *J Am Med Inform Assoc* 2004;11:78-86.
- Jordan K, Clarke AM, Symmons DP *et al.* Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. *Br J Gen Pract* 2007;57:7-14.
- Jordan KP, Joud A, Bergknot C *et al.* International comparisons of the consultation prevalence of musculoskeletal conditions using population-based healthcare data from England and Sweden. *Ann Rheum Dis* 2014;73:212-8.
- Herrett E, Gallagher AM, Bhaskaran K *et al.* Data resource profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol* 2015;44:827-36.
- Jordan H, Roderick P, Martin D. The Index of Multiple Deprivation 2000 and accessibility effects on health. *J Epidemiol Community Health* 2004;58:250-7.

- 24 Zghebi SS, Rutter MK, Ashcroft DM *et al.* Using electronic health records to quantify and stratify the severity of type 2 diabetes in primary care in England: rationale and cohort study design. *BMJ Open* 2018;8:e020926.
- 25 Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. *BMJ Open* 2016;6:e010364.
- 26 Price AJ, Ogollah R, Kang S *et al.* Determining responsiveness and meaningful changes for the Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal care pathways. *BMJ Open* 2019; 9:e025357.
- 27 NHS Digital. Health Survey for England 2017 Quick Guide, December 2018. <https://files.digital.nhs.uk/86/F57D18/HSE17-Quick-Guide-rep.pdf> (22 September 2020, last accessed).
- 28 NHS England. GP Patient Survey 2017. 2017.
- 29 Shah AD, Bailey E, Williams T *et al.* Natural language processing for disease phenotyping in UK primary care records for research: a pilot study in myocardial infarction and death. *J Biomed Semantics* 2019; 10(Suppl 1):20.

A 2nd generation, JAK1 preferential inhibitor for moderate to severe RA¹⁻⁶

While 1st generation JAK inhibitors are relatively non-selective,²⁻⁶ JYSELECA has over 5x greater potency for JAK1 over JAK2/3 and TYK2^{1*}

Balancing sustained efficacy⁷⁻¹¹ with acceptable tolerability^{1,12}

Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs.¹ May be used as monotherapy or in combination with methotrexate.¹

*From biochemical assays, the clinical relevance of which is uncertain. JAK, Janus kinase; RA, rheumatoid arthritis; TYK, tyrosine kinase.

Learn more at
strengthofbalance.co.uk

Refer to Summary of Product Characteristics (SmPC) before prescribing, and for full prescribing information.

JYSELECA[®] filgotinib 100 mg or 200 mg film-coated tablets.
Indication: Jyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX). **Dosage: Adults:** 200 mg once daily. Taken orally with/without food. It is recommended that tablets are swallowed whole. **Laboratory Monitoring:** Refer to the SmPC for information regarding laboratory monitoring and dose initiation or interruption. **Elderly:** A starting dose of 100 mg once daily is recommended for patients aged 75 years and older as clinical experience is limited. **Renal impairment:** No dose adjustment required in patients with estimated creatinine clearance (CrCl) ≥ 60 mL/min. A dose of 100 mg of filgotinib once daily is recommended for patients with moderate or severe renal impairment (CrCl 15 to < 60 mL/min). Not recommended in patients with CrCl < 15 mL/min. **Hepatic impairment:** Mild/moderate hepatic impairment: no dose adjustment required. Severe hepatic impairment: not recommended. **Children (< 18 years):** Safety and efficacy not yet established. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Active tuberculosis (TB) or active serious infections. **Pregnancy/Precautions:** See SmPC for full information. **Immunosuppression:** Combination use with immunosuppressants e.g. ciclosporin, tacrolimus, biologics or other Janus kinase (JAK) inhibitors is not recommended as a risk of additive immunosuppression cannot be excluded. **Infections:** Infections, including serious infections such as pneumonia and opportunistic infections e.g. tuberculosis (TB), oesophageal candidiasis, and cryptococcosis have been reported. Risk benefit should be assessed prior to initiating in patients with risk factors for infections (see SmPC). Patients should be closely monitored for the development of signs and symptoms of infections during and after filgotinib treatment. Treatment should be interrupted if the patient

is not responding to antimicrobial therapy, until infection is controlled. There is a higher incidence of serious infections in the elderly aged 75 years and older, caution should be used when treating this population. **Tuberculosis:** Patients should be screened for TB before initiating filgotinib, and filgotinib should not be administered to patients with active TB. **Viral reactivation:** Cases of herpes virus reactivation (e.g., herpes zoster) were reported in clinical studies (see SmPC). If a patient develops herpes zoster, filgotinib treatment should be temporarily interrupted until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should be performed. **Malignancy:** Immunomodulatory medicinal products may increase the risk of malignancies. Malignancies were observed in clinical studies (see SmPC). **Fertility:** In animal studies, decreased fertility, impaired spermatogenesis, and histopathological effects on male reproductive organs were observed (see SmPC). The potential effect of filgotinib on sperm production and male fertility in humans is currently unknown. **Haematological abnormalities:** Do not start therapy, or temporarily stop, if Absolute Neutrophil Count (ANC) $< 1 \times 10^9$ cells/L, ALC $< 0.5 \times 10^9$ cells/L or haemoglobin < 8 g/dL. Temporarily stop therapy if these values are observed during routine patient management. **Vaccinations:** Use of live vaccines during, or immediately prior to, filgotinib treatment is not recommended. **Lipids:** Treatment with filgotinib was associated with dose dependent increases in lipid parameters, including total cholesterol, and high-density lipoprotein (HDL) levels, while low density lipoprotein (LDL) levels were slightly increased (see SmPC). **Cardiovascular risk:** Rheumatoid arthritis patients have an increased risk for cardiovascular disorders. Patients should have risk factors (e.g., hypertension, hyperlipidaemia) managed as part of usual standard of care. **Venous thromboembolism:** Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving JAK inhibitors including filgotinib. Caution should be used in patients with risk factors for DVT/PE, such as older age, obesity, a medical history of DVT/PE, or patients undergoing surgery, and prolonged

immobilisation. **Lactose content:** Contains lactose; patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take filgotinib. **Pregnancy/Lactation:** Filgotinib is contraindicated in pregnancy. Filgotinib should not be used during breast-feeding. Women of childbearing potential must use effective contraception during and for at least 1 week after cessation of treatment. **Driving/Using machinery:** No or negligible influence, however dizziness has been reported. **Side effects:** See SmPC for full information. **Common ($\geq 1/100$ to $< 1/10$):** nausea, upper respiratory tract infection, urinary tract infection and dizziness. **Uncommon ($\geq 1/1000$ to $< 1/100$):** herpes zoster, pneumonia, neutropenia, hypercholesterolaemia and blood creatine phosphokinase increase. **Serious side effects:** See SmPC for full information. **Legal category:** POM **Pack:** 30 film-coated tablets/bottle **Price:** UK Basic NHS cost: £863.10 **Marketing authorisation number(s):** Great Britain Jyseleca 100mg film-coated tablets PLGB 42147/0001 Jyseleca 200mg film-coated tablets PLGB 42147/0002 Northern Ireland Jyseleca 100mg film-coated tablets EU/1/20/1480/001 EU/1/20/1480/002 Jyseleca 200mg film-coated tablets EU/1/20/1480/003 EU/1/20/1480/004 **Further information:** Galapagos UK, Belmont House, 148 Belmont Road, Uxbridge UB8 1QS, United Kingdom 00800 7878 1345 medicalinfo@glpg.com Jyseleca[®] is a trademark. **Date of Preparation:** January 2022 UK-RA-FIL-202201-00019

Additional monitoring required

Adverse events should be reported.
 For Great Britain and Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).
 Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 00800 7878 1345

References: 1. JYSELECA SPC. Available at: www.medicines.org.uk. Last accessed: June 2022. 2. Angelini J, et al. *Biomolecules* 2020;10(7):E1002. 3. Banerjee S, et al. *Drugs* 2017;77:521-546. 4. O'Shea JJ, et al. *Nat Rev Rheumatol* 2013;9(3):173-182. 5. Traves PG, et al. *Ann Rheum Dis* 2021;01-11. 6. McInnes IB, et al. *Arthr Res Ther* 2019;21:183. 7. Combe B, et al. *Ann Rheum Dis* 2021;doi:10.1136/annrheumdis-2020-219214. 8. Genovese MC, et al. *JAMA* 2019;322(4):315-325. 9. Westhovens R, et al. *Ann Rheum Dis* 2021;doi:10.1136/annrheumdis-2020-219213. 10. Combe B, et al. *Arthritis Rheumatol* 2021;73(suppl 10). <https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-filgotinib-treatment-in-an-ongoing-long-term-extension-trial-of-ra-patients-with-inadequate-response-to-mtx-initially-treated-with-filgotinib-or-adalimumab-during-th/>. Last accessed: June 2022. 11. Buch MH, et al. *Arthritis Rheumatol* 2021;73(suppl 10). <https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-ongoing-filgotinib-ra-long-term-extension-trial-of-biologic-dmard-inadequate-responders-initially-on-filgotinib-or-placebo-in-a-phase-3-trial/>. Last accessed: June 2022. 12. Winthrop K, et al. *Arthritis Rheumatol* 2021;73(suppl 10). Available at: <https://acrabstracts.org/abstract/integrated-safety-analysis-update-for-filgotinib-in-patients-with-moderately-to-severely-active-rheumatoid-arthritis-receiving-treatment-over-a-median-of-2-2-years/>. Last accessed: June 2022.

Galapagos

June 2022 GB-RA-JY-202205-00033

JYSELECA, GALAPAGOS and the JYSELECA and GALAPAGOS logos are registered trademarks of Galapagos NV.
 © 2022 Galapagos NV. All rights reserved.